Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G, Fabi A, Bighin C, Riccardi F, Cianniello D, De Laurentiis M, Puglisi F, Pelizzari G, Bonotto M, Russo S, Frassoldati A, Pazzola A, Montemurro F, Lambertini M, Guarneri V, Cognetti F, Locci M, Generali D, Conte P, De Placido S, Giuliano M, Arpino G, Del Mastro L. Schettini F, et al. Among authors: conte b, conte p. ESMO Open. 2021 Apr;6(2):100099. doi: 10.1016/j.esmoop.2021.100099. Epub 2021 Apr 2. ESMO Open. 2021. PMID: 33819752 Free PMC article.
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C, Tagliamento M, Viglietti G, Del Mastro L, de Azambuja E, Lambertini M. Poggio F, et al. Among authors: conte b. ESMO Open. 2018 Jun 20;3(4):e000361. doi: 10.1136/esmoopen-2018-000361. eCollection 2018. ESMO Open. 2018. PMID: 29942664 Free PMC article.
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study.
Lambertini M, Fontana V, Massarotti C, Poggio F, Dellepiane C, Iacono G, Abate A, Miglietta L, Ferreccio C, Pescio MC, Conte B, Blondeaux E, Bighin C, D'Alonzo A, Vaglica M, Zanardi E, Boccardo F, Ballestrero A, Anserini P, Del Mastro L. Lambertini M, et al. Among authors: conte b. Breast. 2018 Oct;41:51-56. doi: 10.1016/j.breast.2018.06.012. Epub 2018 Jun 22. Breast. 2018. PMID: 30007268
Management of young women with early breast cancer.
Poggio F, Lambertini M, Bighin C, Conte B, Blondeaux E, D'Alonzo A, Dellepiane C, Boccardo F, Del Mastro L. Poggio F, et al. Among authors: conte b. ESMO Open. 2018 Nov 14;3(Suppl 1):e000458. doi: 10.1136/esmoopen-2018-000458. eCollection 2018. ESMO Open. 2018. PMID: 30559981 Free PMC article.
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review.
Poggio F, Lambertini M, Bighin C, Conte B, Blondeaux E, D'Alonzo A, Dellepiane C, Buzzatti G, Molinelli C, Boccardo F, Del Mastro L. Poggio F, et al. Among authors: conte b. Clin Med Insights Reprod Health. 2019 Jul 31;13:1179558119864584. doi: 10.1177/1179558119864584. eCollection 2019. Clin Med Insights Reprod Health. 2019. PMID: 31391786 Free PMC article. Review.
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM).
Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Dieci MV, et al. Among authors: conte b. Cancers (Basel). 2019 Aug 8;11(8):1137. doi: 10.3390/cancers11081137. Cancers (Basel). 2019. PMID: 31398896 Free PMC article.
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L; GIM2 investigators. Lambertini M, et al. Among authors: conte b. Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4. Int J Cancer. 2020. PMID: 31724170
131 results